Address correspondence to Dr Jukka Putaala, Neurocenter, Helsinki University Hospital, Haartmaninkatu 4, 00290, Helsinki, Finland, email@example.com.
RELATIONSHIP DISCLOSURE: Dr Putaala has served on the scientific advisory board for Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer Inc, and Portola Pharmaceuticals, Inc; is an editorial board member of the European Stroke Journal; and is a visiting editor for Terve Media. Dr Putaala has received compensation for lectures for Abbott, Bayer AG, Boehringer Ingelheim, and Bristol-Myers Squibb/Pfizer Inc and for research collaboration for BCB Medical Ltd, Bittium, Nokia Technologies, and Vital Signum. Dr Putaala has received research funding from the Academy of Finland, Business Finland, Hospital District of Helsinki and Uusimaa, Pfizer Inc, and St. Jude Medical, Inc, and owns stock in Vital Signum.
UNLABELED USE OF PRODUCTS/INVESTIGATIONAL USE DISCLOSURE: Dr Putaala reports no disclosure.